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Fanconi anemia (FA) is a rare human genetic disorder characterized by developmental
defects, bone marrow failure and cancer predisposition, primarily due to a deficiency
in the repair of DNA interstrand crosslinks (ICLs). ICL repair through the FA DNA repair
pathway is a complicated multi-step process, involving at least 19 FANC proteins and
coordination of multiple DNA repair activities, including homologous recombination,
nucleotide excision repair and translesion synthesis (TLS). SUMOylation is a critical
regulator of several DNA repair pathways, however, the role of this modification
in controlling the FA pathway is poorly understood. Here, we summarize recent
advances in the fine-tuning of the FA pathway by small ubiquitin-like modifier (SUMO)-
targeted ubiquitin ligases (STUbLs) and other SUMO-related interactions, and discuss
the implications of these findings in the design of novel therapeutics for alleviating
FA-associated condition, including cancer.
Keywords: Fanconi anemia (FA), SUMOylation, SUMO-targeted ubiquitin ligases (STUbLs), SUMO proteases
(SENPs), SUMO-interaction motifs (SIMs), SUMO-like domains (SLDs), deubiquitinases (DUBs), DNA interstrand
crosslinks (ICLs)
FANCONI ANEMIA (FA) DNA REPAIR PATHWAY
Fanconi anemia is a very rare autosomal recessive disease (occurring in just 1 of every
100,000 births), typically distinguished by bone marrow abnormalities, cancer predisposition,
and congenital anomalies (Kee and D’Andrea, 2012). Patients with this disease exhibit defects
in the repair of interstrand crosslinks (ICLs), DNA lesions which hook bases of opposing DNA
strands together, and are consequently hypersensitive to crosslinking agents such as cisplatin,
diepoxybutane (DEB), and mitomycin C (MMC) (Noll et al., 2006). Despite the low prevalence
of the FA disease, the complex pathway involved in the recognition and repair of ICLs orchestrates
multiple DNA repair processes, such as homologous recombination (HR) and translesion synthesis
(TLS), making FA an important model in the study of DNA repair signaling.
To date, 19 FANC proteins have been identified in the FA pathway, which fall into three distinct
functional groups. One group is the FA core complex, consisting of FANCA, B, C, E, F, G, L,
and M, which together with three Fanconi associated proteins (FAAP20, FAAP24, and FAAP100)
functions as an E3 ubiquitin ligase (Garcia-Higuera et al., 2001; Meetei et al., 2003; Ciccia et al.,
2007; Ling et al., 2007; Leung et al., 2012). Upon pathway induction by DNA damage or replication
stress, the targeting components of the FA core, FANCM and FAAP24, bind chromatin and recruit
the FA core complex (Qiao et al., 2001; Kim et al., 2008). A histone-fold-containing complex
consisting of MHF1-MHF2 proteins facilitates the recruitment of FANCM to chromatin to enhance
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pathway activation (Singh et al., 2010; Yan et al., 2010). The FA
core complex subsequently monoubiquitylates group II proteins,
FANCI and FANCD2, which associate to form a heterodimer
called the ID complex (Garcia-Higuera et al., 2001; Sims et al.,
2007; Smogorzewska et al., 2007). This monoubiquitylation of the
ID complex localizes it to chromatin, where it recruits the group
III effector proteins to initiate downstream ICL repair.
Following ID monoubiquitylation, a complex series of steps
ensues to complete ICL repair. First, the mono-ubiquitinated ID
complex serves as a scaffold for recruitment of several nucleases,
which make nucleolytic incisions flanking the ICL to unhook the
crosslink. These nucleases include SLX4 (discussed in more detail
below), ERCC1-XPF1, and MUS81-EME1 structure-specific
endonucleases (Hanada et al., 2006; Knipscheer et al., 2009;
Stoepker et al., 2011; Klein Douwel et al., 2014). Cross-linked
nucleotides on the complementary strand are subsequently
bypassed by the process of TLS, which involves specialized
Y-family polymerases such as polζ and REV1 (Räschle et al.,
2008; Kim et al., 2012; Budzowska et al., 2015). The nucleolytic
incisions result in a double strand break (DSB) in the DNA, which
is repaired by HR (discussed below), and nucleotide excision
repair (NER) fills the remaining gap (Räschle et al., 2008; Kim and
D’Andrea, 2012). Finally, in the last step, the deubiquitinating
(DUB) complex USP1-UAF1 removes monoubiquitin from the
ID complex, allowing for pathway regeneration (Nijman et al.,
2005; Cohn et al., 2007) (Figure 1). For more extensive reviews
on the steps of the FA pathway, please refer to the following
reviews: (Kim and D’Andrea, 2012; Walden and Deans, 2014;
Duxin and Walter, 2015). Despite extensive study, it is likely
that additional aspects of FA pathway activation and regulation
remain unidentified, prompting recent studies of other regulatory
proteins and post-translational modifications (PTMs) involved in
the FA pathway.
CONTROL OF SIGNALING PATHWAYS
BY SUMOylation
In addition to ubiquitin signaling, modification of proteins
by small ubiquitin-like modifier (SUMO) has been implicated
in several aspects of cellular signaling. Similar to protein
ubiquitylation, the process of activating and conjugating SUMO
modifications to substrates involves an E1-E2-E3 enzyme
cascade. SUMO proteins are initially translated as immature
precursors that must be processed by proteases to a mature
form containing a C-terminal diglycine motif. This mature form
of SUMO subsequently becomes bound by an E1 enzyme that
activates SUMO through sequential adenylation and thioester
bond formation. SUMO is then passed to a single E2 conjugating
enzyme, ubiquitin-like conjugating enzyme 9 (Ubc9), that
transfers the SUMO to substrate accepter lysine residues with
the help of E3 protein ligases. Protein SUMOylation is mediated
by several SUMO E3 ligases in mammalian cells, including
those of the PIAS family: PIAS1, PIAS2 (PIASxα/β), PIAS3, and
PIAS4 (PIASy). These E3 enzymes facilitate SUMO conjugation
either by promoting specificity to substrate recruitment by
E2∼SUMO, or by stimulating the discharge of SUMO to
substrates (Gareau and Lima, 2010). The E2 enzyme Ubc9
recognizes its substrates through the consensus SUMOylation
motif, 9KxE/D, where 9 is a large hydrophobic residue
(Rodriguez et al., 2001). Conversely, SUMO can also be de-
conjugated from substrates through the activity of SUMO specific
proteases (SENPs), making this a highly dynamic modification
analogous to ubiquitylation and phosphorylation (Kumar and
Zhang, 2015).
Another family of proteins called SUMO-targeted ubiquitin
ligases (STUbLs) has also been characterized recently that
connects the processes of SUMOylation with ubiquitylation.
Uniquely, STUbL enzymes recognize their substrates through
SUMO-interaction motifs (SIMs), short hydrophobic peptide
sequences that mediate non-covalent attachments with SUMO
(Perry et al., 2008). Often, STUbL enzymes promote the specific
recruitment of proteins containing both ubiquitin-interacting
motifs (UIMs) and SIMs through the synthesis of SUMO-
ubiquitin conjugate chains. As an example, the RAP80 subunit of
the BRCA1 complex uses both its SIM and UIM motifs to bind
SUMO-ubiquitin conjugate chains synthesized by the STUbL
RNF4 for efficient recruitment to DSBs immediately following
DNA damage (Guzzo et al., 2012; Hu et al., 2012). By promoting
the degradation of previously SUMOylated target proteins,
STUbL enzymes play important roles as global regulators of
SUMOylation levels. Imbalances in global protein SUMOylation
levels can have several adverse cellular consequences, including
genome instability and sensitivity to genotoxic stress (Perry et al.,
2008).
Small ubiquitin-like modifier and SUMO-like modifications
can influence a wide variety of cellular signaling pathways by
directing changes in protein-protein interactions, altering protein
intracellular localization, directing protein turnover (via STUbL
enzymes described above), or changing protein activity. Despite
its importance in these other signaling pathways (reviewed
in Gareau and Lima, 2010), a functional role for ubiquitin-
SUMO crosstalk in the Fanconi Anemia pathway has not been
defined until recently. This review highlights new evidence of
FA pathway modulation by SUMO modifications and SUMO-
like interactions, and describes the impact of these observations
on our understanding of FA pathway regulation and disease
treatment.
ROLE OF FANCA SUMOylation
One example of how SUMOylation contributes to FA pathway
regulation is through promoting the polyubiquitylation of FA
core complex member FANCA. A recent study from the
D’Andrea lab identified a patient with a point mutation in
FANCA (FANCAI935S) that fails to bind the FAAP20 subunit
of the FA core complex, leading to decreased FANCA protein
levels. In uncovering the mechanism behind this decreased
stability of FANCA, the authors discovered that defective FAAP20
binding by the FANCA mutant leads to increased exposure of
a SUMOylation site on FANCA at residue K921, which in turn
promotes UBC9-mediated SUMOylation, polyubiquitylation by
the STUbL RNF4, and proteasome-dependent degradation of
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FIGURE 1 | The ICL repair pathway. The FANCM-FAAP24 complex first recognizes stalled replication structures, and recruits the FA core complex to the ICL.
ATR-Chk1 phosphorylates and activates multiple components, including FANCA, E, I, and D2, which is required for monoubiquitylation of the ID complex by the FA
core complex. Upon monoubiquitylation, the activated ID complex localizes to chromatin and coordinates the activities of downstream nucleases that create
incisions around the crosslink. The resulting structure is then repaired by multiple processes, involving lesion bypass by TLS polymerases, HR, and NER. Finally, the
USP1-UAF1 DUB complex removes monoubiquitin from the ID complex to complete repair. See accompanying text for more details. Yellow spheres indicate
Fanconi Anemia-associated proteins (FAAPs) FAAP20, FAAP24, and FAAP100. Targets for SUMOylation highlighted in this review are denoted in green.
FANCA. Failure of the FANCA mutant to bind FAAP20
still allows efficient FANCD2 monoubiquitylation, but leads
to an inability to properly recruit the REV1 translesion
polymerase (Kim et al., 2012), contributing to lower rates of
TLS-mediated mutagenesis. On the other hand, the authors
showed that wild-type FANCA is also subject to SUMOylation
and RNF4-mediated polyubiquitylation, but to a lesser degree,
and depletion of RNF4 contributed to increased MMC sensitivity
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(Xie et al., 2015) (Figure 2A). Taken together, these results
indicate that the regulated release of FAAP20 from FANCA
is a normal critical step in the FA pathway and suggest
that failure to properly release FANCA from the FA core
complex could contribute to pathway disruption and genome
instability.
SUMOylation OF THE ID COMPLEX FOR
THE FA PATHWAY
As discussed previously, ID complex monoubiquitylation is
removed by the USP1-UAF1 (WDR48) DUB complex, allowing
for FA pathway regeneration (Nijman et al., 2005; Cohn
et al., 2007). Evidence shows that depletion of USP1 in either
murine models or chicken DT40 cells enhances chromatin
loading of the ID complex in the absence of exogenous DNA
damage (Oestergaard et al., 2007; Kim et al., 2009), but only
to similar levels as observed following mitomycin C (MMC)
treatment, suggesting the existence of alternative mechanisms to
restrain ID complex loading at DNA lesions. Work by Gibbs-
Seymour et al. (2015) demonstrates that direct SUMOylation
of the ID complex can also stimulate the removal of activated
ID complexes at sites of damage, thereby controlling ID
complex dosage at DNA lesions. ID complex SUMOylation
is dependent on the ATR kinase and two SUMO E3 ligases,
PIAS1 and PIAS4, and is antagonized by the SUMO protease
SENP6. Following SUMOylation, the STUbL RNF4 targets the
ID complex for polyubiquitylation, ultimately promoting ID
complex chromatin extraction from DNA lesions by the DVC1-
p97 ubiquitin segregase complex. This ubiquitin-SUMO network
thereby helps fine-tune ID complex recruitment to DNA damage
sites. The authors further show that dysregulation of this
process through expression of a SUMOylation-deficient FANCI
mutant results in increased DNA damage and MMC sensitivity,
illustrating the importance of this mechanism for limiting ID
complex dosage at DNA lesions (Gibbs-Seymour et al., 2015)
(Figure 2B).
An obvious follow-up question to this study is: why is
it so important to precisely regulate ID complex dosage at
DNA damage sites by this elaborate mechanism? The authors
suggest that this regulation by ubiquitin-SUMO crosstalk
could help prevent excessive nucleolytic processing of DNA,
downstream of ID complex monoubiquitylation. Like USP1-
mediated deubiquination, SUMOylation of ID proteins could also
be an important mechanism allowing for ID complex recycling
and FA pathway regeneration. Future work will be needed to
further understand mechanistically how dysregulation of ID
complex dosage at DNA damage sites contributes to genome
instability.
SLX4 ACTS AS A SUMO E3 LIGASE
One of the key steps in ICL repair is nucleolytic excision of
the cross-link and downstream repair of the resulting DSB
by HR. A key player that coordinates these complex repair
processes is the SLX4 protein. Together with its activating
subunit, SLX1, SLX4 associates with XPF-ERCC1 and MUS81-
EME1 structure-specific endonucleases to cleave branched DNA
structures (Andersen et al., 2009; Munoz et al., 2009; Stoepker
et al., 2011). SLX4 additionally interacts with the mismatch
repair proteins MSH2-MSH3 and is required for telomere
stability through association with TRF2 (Wan et al., 2013). SLX1-
SLX4 complexes serve as HJ resolvases and process multiple
recombination intermediates (Fekairi et al., 2009). Thus, SLX4
serves as a scaffold for many different nucleases involved in ICL
and HR repair, but our understanding of how these interactions
are orchestrated to direct specific repair outcomes has been
limited.
New studies from the Gaillard, Vertegaal, and Zou labs
have shed light on SLX4 regulation, showing that SUMO and
ubiquitin modifications are involved in directing the different
activities of the SLX4 complex. Guervilly et al. (2015) made
the surprising discovery that the SLX4 complex is a SUMO E3
ligase that SUMOylates SLX4 itself. SUMOylation by SLX4 is
dependent on an interaction with the charged UBC9∼SUMO
E2 enzyme as well as newly identified SIMs in SLX4. Studies
from the Vertegaal lab identified three such SIMs in the SLX4
protein and showed that these motifs were critical for proper
ICL repair and targeting of SLX4 to PML nuclear bodies and
laser-induced DNA damage sites (González-Prieto et al., 2015).
In addition to SUMOylating itself, SLX4 also targets the XPF
subunit of the repair endonuclease XPF-ERCC1 for SUMO
modification (Guervilly et al., 2015). Unexpectedly, the BTB
domain of SLX4, which facilitates XPF targeting (Andersen et al.,
2009), was specifically required for SUMOylation of XPF in vivo
and in vitro, showing an additional role for the BTB domain
outside of XPF binding (Figure 2C). At one extreme, chronic
overexpression of SLX4 induces global replication stress and is
extremely cytotoxic, which the authors suggest are consequences
of extensive nucleolytic processing and chromatid breakage.
On the other hand, the SUMO E3 ligase activity of SLX4
facilitates expression of common fragile sites (CFS), unstable
genomic loci that are difficult to replicate. In fact, failure to
localize SLX4 to CFS is associated with increased anaphase
bridges and mitotic catastrophe. Therefore, on a global scale,
increased SUMO ligase activity of SLX4 is detrimental as it
contributes to replication stress, but is necessary to prevent
mitotic catastrophe following CFS expression (Guervilly et al.,
2015).
Ouyang et al. (2015) made similar findings about the
involvement of SUMOylation in SLX4 activity. Namely,
they also discovered that SLX4 binds SUMO2/3 chains via
SIMs in a manner dependent on charged UBC9, and that
SUMO interactions are important for suppressing fragile
site instability and processing of CPT-induced replication
intermediates. However, the authors extend these findings by
directly comparing SLX4 targeting via its ubiquitin-binding
zinc finger (UBZ) domains versus its SIM domains. While
the UBZs of SLX4 are critical in ICL repair, the SIMs
of SLX4 are instead more important for binding DNA
damage sensors such as RPA, the MRN complex, and the
telomere binding protein TRF2. Thus, the UBZs and SIMs
Frontiers in Genetics | www.frontiersin.org 4 April 2016 | Volume 7 | Article 61
fgene-07-00061 April 15, 2016 Time: 15:59 # 5
Coleman and Huang SUMOylation and the Fanconi Anemia Pathway
FIGURE 2 | Control of the FA pathway by SUMO and SUMO-like modifications. (A) Regulated release of the FAAP20 subunit from FANCA is required for
SUMOylation of FANCA via the E2 conjugating enzyme Ubc9. Removal of FAAP20 inhibits the recruitment of the downstream TLS polymerase REV1 during ICL
repair, resulting in decreased TLS-mediated mutagenesis. SUMOylation of FANCA subsequently triggers RNF4-mediated polyubiquitylation and
proteasome-mediated degradation. (B) The ID complex is targeted for SUMOylation in a manner dependent on the activities of the ATR kinase, the FA core complex,
and the SUMO E3 ligases PIAS1/PIAS4. Alternatively, SUMOylation can be removed by the SUMO protease SENP6. SUMOylation of the ID complex allows for
recognition by RNF4, leading to ID complex polyubiquitylation and removal from damage sites via the DVC1-p97 segregase complex. (C) The SLX4 complex acts as
a SUMO E3 ligase by triggering its own SUMOylation in addition to that of the DNA repair/recombination endonuclease XPF. This SLX4-dependent SUMOylation is
dependent on the E2 Ubc9, as well as its own SIMs and BTB domains, and is important to prevent mitotic catastrophe following CFS expression. (D) The SUMO E3
ligases PIAS1 and PIAS4 promote DSB repair by localizing to damage sites and SUMOylating multiple target proteins, including BRCA1 and 53BP1. This
SUMOylation is required for proper ubiquitin-adduct formation mediated by RNF8, RNF168, and BRCA1 to initiate a DNA damage response (DDR). (E) The
SUMO-like domain SLD2 of UAF1 directs USP1-UAF1 targeting to its substrates via SIMs located within FANCI and the PCNA-interacting protein hELG1. These
SLD-SIM interactions regulate deubiquitylation of FANCD2 and PCNA-Ub substrates, respectively, to coordinate HR and TLS activities during FA DNA repair.
Frontiers in Genetics | www.frontiersin.org 5 April 2016 | Volume 7 | Article 61
fgene-07-00061 April 15, 2016 Time: 15:59 # 6
Coleman and Huang SUMOylation and the Fanconi Anemia Pathway
of SLX4 are functionally distinct, providing a mechanism for
targeting SLX4 in different repair contexts (Ouyang et al.,
2015).
ROLE OF SUMOylated PCNA IN
MAMMALIAN CELLS
The FA pathway is important for activation of HR-mediated
repair, a DSB repair mechanism that uses an intact sister
chromatid as a repair template (review in Moynahan and
Jasin, 2010). While HR has the advantage of being an error-
free mode of repair as opposed to the non-homologous end
joining (NHEJ) pathway, inappropriate hyperrecombination is
associated with genomic instability and cancer (Martin et al.,
2007). How the FA pathway coordinates crosslink repair and
HR appropriately has been a poorly understood topic. It is
known that in budding yeast, the UvrD domain helicase Srs2
limits inappropriate HR by removing RAD51 nucleofilaments
from ssDNA at an early step in the HR pathway (Papouli
et al., 2005). A homolog for Srs2 with similar antirecombinase
activity had not been identified in human cells, however,
prompting a recent study by the D’Andrea lab to identify
novel HR regulators in mammalian cells. The authors identified
C12orf48 as an anti-recombinase in human and chicken DT40
cells that specifically interacts with a PCNA-SUMO fusion
protein in vitro. They named this protein PCNA associated
recombination inhibitor (PARI). Similar to Srs2 in yeast, PARI
restricts recombination by interfering with RAD51-DNA HR
structures and is required for genome stability. Interestingly,
PARI knockdown in FA cells, which are deficient in HR
(Nakanishi et al., 2005), improves genome instability by
increasing recombination frequency (Moldovan et al., 2012).
These results indicate that manipulation of PARI levels could be
an effective chemoprotective approach in HR-deficient cancers.
Nevertheless, several key questions still remain pertaining to the
role and recruitment of PARI to the replication fork, including
whether SUMOylation of mammalian PCNA exists and whether
PARI is truly the long sought-after functional human homolog of
budding yeast Srs2.
ROLE OF SUMOylation IN HR REPAIR
Following unhooking of an ICL by nucleolytic incisions, a
DSB is generated that must be repaired by HR. Current
evidence demonstrates a role for SUMOylation in coordinating
this DSB repair step. SUMO E3 ligases PIAS1 and PIAS4
accumulate at DNA damage sites in mammalian cells, where
they target multiple substrates for SUMO modification, including
53BP1 and BRCA1, to damage foci. SUMOylation facilitates the
localization of these DNA repair proteins to DSB sites and also
is required for RNF8 and RNF168-mediated ubiquitylation of
target proteins (including H2A/X) to signal downstream repair
(Galanty et al., 2009). In particular, SUMOylation of BRCA1
by PIAS SUMO E3 ligases increases its ubiquitin ligase activity,
identifying it as a STUbL (Morris et al., 2009). In addition to
BRCA1, another STUbL, RNF4, was identified that promotes
DSB repair by regulating the turnover of DSB-responsive
factors MDC1 and replication protein A (RPA), allowing for
recruitment of factors necessary for DSB repair by HR (Galanty
et al., 2012). Through the combination of these mechanisms
(Figure 2D), SUMO-ubiquitin crosstalk amplifies DSB signaling
to promote efficient DSB repair. Although likely, it is currently
unclear whether regulation of BRCA1 by SUMOylation plays
a role in the repair of ICLs as part of the Fanconi Anemia
pathway.
ROLE OF SUMO-LIKE DOMAINS (SLDs)
IN DUB-SUBSTRATE INTERACTIONS
While the importance of USP1/UAF1-mediated deubiquitylation
of FANCD2 has been clearly established (Nijman et al., 2005;
Oestergaard et al., 2007; Kim et al., 2009), the question
of how USP1/UAF1 is targeted to the FANCI/FANCD2
heterodimer has remained elusive until recently. Yang et al.
(2011) discovered that this targeting mechanism involves SUMO-
like domains (SLD1 and SLD2) at the C-terminus of UAF1,
which bind directly to SIM motifs of FANCI. Likewise, the
SLD2 domain of UAF1 also binds to the SIM on hELG1
to direct USP1/UAF1 binding to another important substrate,
PCNA-Ub (Huang et al., 2006). This SLD-SIM interaction is
critical for FA pathway function, as deletion of the SLD2
sequence of UAF1 or the SIM of FANCI leads to deficient
FANCD2 monoubiquitylation and DNA repair. Thus, SLD-
SIM interactions provide a means for the regulated delivery of
USP1/UAF1 DUB complex to its substrates for efficient ICL
repair (Yang et al., 2011) (Figure 2E). As UAF1 is a highly
abundant protein with many diverse binding partners, this
study also points to the possibility that SLD-SIM targeting
may also play broader roles not only in DNA repair, but as a
general means to sort intracellular proteins involved in other
processes.
FUTURE PERSPECTIVES
In summary, the above studies clearly demonstrate the
importance of SUMO and SUMO-like modifications in fine-
tuning FA pathway activation and DNA repair (summarized in
Figure 2). It is probable that findings reported here represent
a small portion of targets controlled by SUMOylation in the
FA pathway, and future work should uncover other unidentified
substrates and SUMO ligases/proteases critical to this process.
These studies also point to the possibility of pharmacologically
targeting SUMO ligases, SIM-SUMO interactions, and SENPs
as a way to manipulate FA pathway activity in FA cells
and HR-defective cancers. Consistent with this notion, several
studies have reported the overexpression of SENPs in various
disease conditions and cancers, prompting recent advancements
in the development of small molecule inhibitors of SENPs
with therapeutic potential (review in Kumar and Zhang,
2015). On the other hand, aggressive modulation of SUMO-
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ubiquitin signaling could also pose a risk for inefficient repair by
the FA pathway and other DNA repair mechanisms. Thus, future
studies are highly necessary to further understand the proper
balance of SUMOylation and ubiquitination activity necessary
for proper FA pathway function, and how dysregulation of
these ubiquitin and ubiquitin-like post-translational modifiers
underlies genome instability.
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